Skip to main content
. Author manuscript; available in PMC: 2015 Mar 20.
Published in final edited form as: Vaccine. 2010 May 26;28(0 2):B25–B31. doi: 10.1016/j.vaccine.2009.10.131

Fig. 3. Plasma viremia post-SHIV-1157ip and SHIV-1157ipd3N4 challenges.

Fig. 3

Viral loads after oral challenge with SHIV-1157ip in plasma of animals of Groups 1 and 2 (A) and 3 (B) and after intrarectal rechallenge with SHIV-1157ipd3N4 of animals of Groups 1 and 2 (C) and 3 (D); viral loads of 8 additional SHIV-1157ipd3N4 challenged control animals are also shown (D). Solid symbols in (A) show viremia levels in those animals of Groups 1 and 2 that were later rechallenged with SHIV-1157ipd3N4. Solid square symbols in (B) and (D) show viremia levels in Group 3 control animal, RAr-9, after each challenge, respectively. The solid circle symbols in (C) highlight undetectable viremia levels of animal RAt-9 after rechallenge. The assay's limit of detection (50 copies/ml plasma) is denoted by dashed, horizontal lines (adapted from [13]).